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SummAry
Thyroid cancer, the most common endocrine malignancy, is often detected in young female patients. Therefore, pregnancy following thy-
roid cancer is not infrequent, and about 10% of thyroid cancers occurring during the reproductive years are diagnosed during pregnancy or 
in the early post-partum period. Differentiated thyroid cancer (DTC) in young people generally has an excellent prognosis, and disease-free 
survival among women with DTC diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar 
disease. however, thyroid cancer detected during pregnancy may cause anxiety about the optimal timing of recommended treatments and 
about both maternal and neonatal morbidity, as weel as pregnancy following a diagnosis of thyroid cancer obviously needs both maternal 
and foetal management. The main objectives in clinical monitoring of pregnant thyroid cancer patients are: 1) to reach an adequate balance 
of maternal calcium and thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation; 2) to 
maintain optimal levels of maternal thyroxin to avoid possible recurrence or spread of disease; and 3) to perform safe follow-up visits for 
the mother and to plan further therapy when needed. Data from a review of the literature and the authors’ own experience show that in 
patients undergoing either suppressive or substitutive thyroxine therapy foetal thyroid growth is normal at ultrasound study, newborn thy-
roid status is normal, and the incidence of maternal morbidity is not influenced by the pregnancy. in this review, the authors underline that 
regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some 
insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated 
thyroid cancer.
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riASSunTo
I carcinomi tiroidei sono la neoplasia endocrina più frequente, si presentano facilmente in età giovanile e nelle donne, quindi una gravi-
danza in seguito ad un tumore tiroideo non è un evento raro, e circa il 10% delle neoplasie tiroidee diagnosticate in età fertile si colloca nel 
periodo della gravidanza o dell’immediato post-partum. I tumori differenziati della tiroide (DTC) hanno in genere una eccellente prognosi, 
e la sopravvivenza libera da malattia nelle donne con DTC diagnosticato durante la gravidanza non sembra differente da quella di pazienti 
non gravide della stessa età e con malattia simile per estensione locale e indici di rischio. Nonostante ciò un tumore diagnosticato in corso 
di gravidanza è ovviamente fonte di ansia non solo per la scelta delle modalità e dei tempi di trattamento, ma anche per la valutazione dei 
rischi materno - fetali associati sia al tumore che alla terapia stessa. Una gravidanza che invece inizi dopo il trattamento per carcinoma 
della tiroide richiede accurati controlli del feto e della madre sia dal punto di vista oncologico che biochimico. Nel monitoraggio di una pa-
ziente in gravidanza con diagnosi di carcinoma tiroideo o già trattata per carcinoma tiroideo gli obbiettivi principali sono: 1) raggiungere 
un buon compenso calcio-vitaminico ma soprattutto un ottimale livello di levo-tiroxina, assolutamente indispensabile per la maturazione 
del sistema nervoso centrale del feto; 2) mantenere livelli di levotiroxina adeguati per evitare possibili recidive di malattia; 3) attuare 
controlli di follow-up sicuri per madre e feto e adatti a pianificare ulteriori terapie se necessario. Dall’analisi dei dati di letteratura e 
dall’esperienza personale degli autori emerge che lo sviluppo fetale è regolare nelle pazienti trattate con levotiroxina  sia a dosaggio sosti-
tutivo che a dosaggio TSH-soppressivo, la tiroide risulta normale all’esame ecografico nel feto e alla valutazione neonatale, e la patologia 
materna non è influenzata dalla gravidanza. In questa review gli autori ricordano con semplici spunti pratici che un’attenta modulazione 
della terapia calcio-vitaminica e della terapia con levotiroxina siano di estrema importanza per il benessere sia della madre che del feto.
pArole ChiAve: Gravidanza • Carcinoma tiroideo • Terapia con tiroxina
Acta Otorhinolaryngol Ital 2011;31:358-365Thyroid cancer in pregnant women
359
Introduction
Thyroid  cancer,  the  most  common  endocrine  malig-
nancy, is often detected in young patients and is more 
frequently diagnosed in women. The median age at di-
agnosis is low, below 40 years in most populations. For 
these reasons, differentiated thyroid cancer (DTC) is 
one of the most common cancers in women in the re-
productive age. hence, thyroid cancer ranks among the 
most common cancers during pregnancy, with a preva-
lence of 3.6-14 per 100,000 live births, mirroring the its 
incidence 1-4.
Therefore, pregnancy in thyroid cancer patients is not un-
usual, and about 10% of thyroid cancers occurring during 
reproductive years are diagnosed during pregnancy or in 
the early post-partum period.
Some data suggest the importance of growth factors (main-
ly TSh, but also hCg) in growth, progression and spread 
of papillary tumours. in vitro oestrogens have been shown 
to down-regulate the niS (sodium iodide symporter) gene 
and promote the production of thyroglobulin (hTg), in-
creasing  hTg-gene  expression  via  oestrogen  receptors 
present in thyroid tissue, without stimulating rapid cell 
proliferation 1 4 5. This could support the hypothesis that 
sex hormones and, therefore, menstrual and reproductive 
events, may modify thyroid cancer risk in women 6, al-
though these associations – which could indicate either a 
causal link or a surveillance bias – may reflect an aetiol-
ogy shared by both the above-mentioned factors and by 
thyroid cancer. however, such a relation has not yet been 
confirmed.
The diagnosis of a tumour during pregnancy obviously 
causes anxiety about the optimal timing of recommended 
treatments and about both maternal and neonatal morbidi-
ty. however, thyroid cancer in young people has generally 
an excellent prognosis, and survival among women with 
thyroid cancer diagnosed during pregnancy may not dif-
fer from that in age-matched non-pregnant women with 
similar disease.
pregnancy is a special situation in oncology: we need to 
control two patients at the same time, and both are vulner-
able. in addition, each situation must be considered in de-
velopment, nothing is static, mainly in the first trimester. 
Finally, thyroid cancer patients often undergo total thy-
roidectomy and thus need adequate supplementation of 
both calcium and thyroxine.
Thus, pregnancy following thyroid cancer needs both 
maternal and foetal control. The main problems are: 
i) to reach an adequate balance of maternal thyroid hor-
mones that is absolutely required by the foetal central 
nervous system for normal maturation 7, ii) to main-
tain maternal levels of l-thyroxin to avoid possible re-
currence or spread of disease, and iii) to perform safe 
follow-up controls for the mother and to plan further 
therapy when needed.
Physiology of pregnancy
1. Thyroid hormones and foetal development
The first endocrine structure to appear during embryonic 
development is the thyroid gland. At 10-12 weeks of em-
bryo  development,  follicles  containing  colloid  become 
visible, and the thyroid is able to incorporate iodine into 
thyroid hormones. Thyroid hormones are major factors 
for the normal development of foetal brain, and until the 
end of the first trimester, when the hypothalamic-pitui-
tary-thyroid axis becomes functional, the foetal brain is 
strictly dependent on local deiodination of maternal thy-
roxine 7-12. Thyroid hormone deficiency may cause severe 
neurologic disorders, resulting from defects in neuronal 
cell differentiation and migration, axonal and dendritic 
outgrowth, myelin formation and synaptogenesis 7 9 13. The 
offspring of women with a serum-free thyroxine (fT4) 
concentration in the lowest decile of the reference range 
at 12 weeks of gestation may have significant delays in 
neurodevelopment. The mother is the only source of foe-
tal thyroid hormones from conception to approximately 
13 weeks of gestation, when foetal thyroid function has 
developed 14-16.
During pregnancy, the mother’s thyroid physiology under-
goes many well-defined changes, leading to an increase 
in thyroid volume which is often associated with higher 
urinary iodine excretion. it is also associated with the for-
mation of new thyroid nodules with the histological fea-
tures of nodular hyperplasia. very early in pregnancy, the 
increase in oestrogen levels causes an approximate dou-
bling in thyroxine-binding globulin (TBg) that can lead to 
an increases in total T4 concentration and a reduced free 
fraction (Table i). in healthy women, the final effect con-
sists of a significant increase in the total thyroxine pool, 
mainly in the first trimester 17-19. This increment may be 
brought about largely by thyroid stimulation induced by 
human chorionic gonadotropin (hCg) through its struc-
tural affinity with thyrotropin (TSh). it can be observed 
that a slight increase in fT4 and a reduction in TSh occur 
between the 9th and 12th weeks of gestation; subsequently, 
hCg levels decrease and TSh reaches normal non-preg-
nant levels. The TSh concentration generally lies within 
the normal range after the 16th to 18th week 11 17 19 20. in 
Table I.  Physiological changes in thyroid function during pregnancy.
Increase Decrease
HCG (TSH–like effect) TSH
TBG, serum total T 4 and T3, T3 and T4 pool size
HTG
Type III 5-deiodinase, iodine clearance, T3 and T4 
degradation
Thyroid volumeB. gibelli et al.
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hypothyroid or thyroidectomized pregnant women, such 
physiological changes obviously cannot occur. Both dur-
ing suppressive or substitutive therapy, l-T4 requirement 
increases very early during pregnancy, reaching a plateau 
after 16th to 20th weeks of gestation, with a required l-T4 
dosage approximately 30 to 50% higher than that admin-
istered before pregnancy.
Besides the well-known association between gestational 
hypothyroidism  and  impaired  intellectual  and  cogni-
tive development in offspring, untreated or inadequately 
treated and subclinical hypothyroidism is associated with 
foetal  loss,  anaemia,  gestational  hypertension  and  pre-
eclampsia, abruption placentae, increased risk of miscar-
riage, foetal growth retardation, perinatal mortality and 
neonatal morbidity 9 13 15-17 21 22. Finally, for thyroid cancer 
patients, hypothyroidism can rise the maternal risk of re-
currence.
Thus, hypothyroidism must be absolutely avoided in all 
pregnant woman, especially in thyroid cancer patients, 
and therefore correct supplementation of thyroxine is of 
extreme importance.
2. Vitamin D requirement during pregnancy
Thyroidectomised patients often need calcium and D vi-
tamin supplementation, and the treatment needs frequent 
adjustment during the pregnancy to prevent maternal and 
neonatal hypocalcemia. During pregnancy vitamin D and 
calcium metabolism undergo significant changes to pro-
vide the calcium needed for maternal skeletal preserva-
tion  and  foetal  skeletal  formation.  increased  intestinal 
calcium absorption seems to be the primary mechanism 
for obtaining extra calcium in physiological pregnancy, 
but frequent nausea and vomiting or sometimes diarrhea 
reduce the amount of calcium absorbed by the mother 23. 
vitamin D does not occur naturally in foods. moreover, 
the usual recommendations to avoid sun exposure reduces 
dermal synthesis of vitamin D3 Although vitamin D is 
undoubtedly important for foetal bone development, we 
know that it plays a much wider role in health and disease 
prevention.
not really a vitamin, D3 is a pro-prehormone made in the 
skin in response to ultraviolet-B light exposure. it is the 
precursor to form 25-hydroxyvitamin D3 [25(oh)D3], a 
prehormone, which is ultimately converted to 1,25-dihy-
droxyvitamin D3 [1,25(oh)2D3], one of the most potent 
steroid hormones known. 1,25(oh)2D may interfere with 
many functions beyond calcium metabolism, such as foe-
tal “imprinting” that may affect neurodevelopment, im-
mune function and chronic disease susceptibility later in 
life, as well as soon after birth 24 25.
The active metabolite of vitamin D, 1,25-dihydroxyvi-
tamin D [1,25(oh)2 D] increases intestinal calcium ab-
sorption and decreases renal calcium excretion, thus in-
creasing the pool of calcium available both for mother 
and foetus. vitamin D and calcium deficiency can lead to 
maternal anorexia with poor weight gain, and impaired 
bone ossification or osteopenia among newborn infant.. 
neonatal hypocalcemia with seizures is not uncommon in 
D-vitamin deficient mothers.
vitamin D is likely safe during pregnancy and breast feeding 
when taken by mouth in recommended amounts, that is 10 
mcg (400 uSp units) of vitamin D daily in normal pregnancy. 
but sometimes thyroidectomised women need more. Dosage 
in excess of 50 mcg (2000 units) per day are not recom-
mended, thus the treatment of postsurgical hypoparatithy-
roid patient calcium supplementation may be required at 
dosage as high as  4 g/day together with  D vitamin.
The range between therapeutic and toxic doses is nar-
row, and vitamin D toxicity, when it occurs, is a serious 
problem. The first sign is a rise in the ratio of calcium 
to creatinine in the urine, which precedes hypercalcemia. 
hypervitaminosis D is thought to be associated with a 
rare infant disease with supravalvular aortic stenosis, elfin 
facies and mental retardation. 
Thus doses of D vitamin and calcium supplementation, 
which  may  differ  from  those  recommended  in  normal 
pregnancy,  need  to  be  carefully  tailored  in  thyroidect-
omised patients. 
Thyroid cancer and pregnancy
Treatment and follow-up of thyroid cancer in pregnant 
women are the same as in non-pregnant patients except 
for the use of radioactive iodine. There are some differ-
ences in the management of the two most important histo-
types: DTC (differentiated thyroid cancer: follicular and 
papillary cancer) and mTC (medullary thyroid cancer) 
just as for non-pregnant patients [Boxes 1-2].
Thyroid  nodules  in  pregnancy  are  often  misdiagnosed 
because of physiological thyroid increases during preg-
nancy, but clinical and ultrasound findings are sufficient 
to suspect malignancy. Skilled examiners and good qual-
ity images with grey-scale and power Doppler uS seem 
more reliable than other techniques in detecting and dif-
ferentiating malignant and benign solid thyroid nodules, 
especially for small lesions. even during pregnancy, uS 
guided fine-needle aspiration biopsy (FnA) is the investi-
gation of choice, thanks to its reliability and safety 19 26.
papillary thyroid cancer is the most common histologi-
cal type detected in pregnant women, and in most series 
90% to 95% of thyroid carcinoma diagnosed are Stage i 
disease, with the majority found in the first trimester of 
pregnancy during the first antenatal visit. The predomi-
nance of papillary cancer may be an important factor fa-
vouring localized disease, as these cancers metastasize 
slowly, and mostly in the lymphatic system, whereas less 
common follicular cancers tend to spread via angio-in-
vasion with a higher frequency of distant metastasis. Al-
though thyroid cancer during pregnancy may have a faster 
growth 27 28 since hormonal factors (mainly hCg) may ac-Thyroid cancer in pregnant women
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celerate tumour progression, the real impact of pregnancy 
seems to be minimal. in fact, the rates of recurrence or 
the disease-free period do not differ between pregnant and 
non-pregnant women affected by the same disease 2 27 29-32. 
hod et al. reported a single case of accelerated tumour 
growth during pregnancy, but this would appear to be an 
exception rather than the rule 29.
in a large retrospective study on 595 pregnancy-associated 
thyroid cancers, yasmeen et al. detected no difference in 
outcome, disease-free survival and morbidity when com-
pared to age-matched non-pregnant women 2. Different-
ly from what is observed in other pregnancy-associated 
cancers, no metastasis of DTC to placenta or foetus has 
been reported. An association between thyroid cancer and 
parity or full-term pregnancy has been assessed in many 
studies without significant or conclusive results 6.
During pregnancy, cellular immunity undergoes changes, 
as reflected by a decrease in T-cell number. pregnancy-
associated immune tolerance, designed for foetal survival, 
might enhance disease progression. however, according 
to literature data and our own experience pregnancy af-
ter thyroid cancer has been shown to have no significant 
effect on morbidity, disease-free period or survival time. 
pregnant women with thyroid cancer have been shown to 
have favourable outcomes regardless of the timing of di-
agnosis 1 32 33.
guidelines for evaluation and treatment of thyroid cancer 
must consider the gestational age but also the patients’ 
desires.  Detecting  a  thyroid  cancer  during  pregnancy 
should not be a reason for termination of pregnancy, and 
in the large majority of cases it does not require urgent 
surgery 4.
The problem of pregnancy-associated thyroid cancer can 
affect three groups of patients:
1. New diagnosis
Patients with no prior history of cancer, in whom a ma-
lignant thyroid nodule is suspected or diagnosed during 
pregnancy.
For these patients, surgery could be safely performed dur-
ing the mid-trimester or delayed until delivery without 
worsening  prognosis  30  34.  Thyroidectomy  during  preg-
nancy has not been associated with adverse maternal or 
neonatal outcomes 35 36. There are no indications for ter-
Box 1. 
Differentiated Thyroid Cancer (DTC) – cancer arising from follicular thyroid cells
Mostly diagnosed in young people, DTC usually has a good prognosis with an overall 90-95% long-term disease-free survival for early stage or low risk tu-
mours, which represent the vast majority of tumours diagnosed below 40-45 years of age. According to the current staging score, DTCs of any dimension, 
even with nodal invasion, for patients below 45 years of age, are classified as Stage I tumours, and usually pregnant patients are below 45 years of age.
Genetic alterations activating a common pathway of the RET-RAS-BRAF signalling cascade and other chromosomal rearrangements have been identi-
fied in most DTC. The existence of common genomic changes between DTC and anaplastic carcinoma may provide convincing proof of the multi-step 
carcinogenesis hypothesis in which cancer cells are produced from well-differentiated benign cells by transformation caused by accumulating damage 
to their genome
Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other 
“non-RET” tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem 
cells instead of differentiated follicular cells. Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some 
cases of unusual, rapidly growing DTC. Both hypotheses would suggest a higher thyroid neoplasm proliferation in stimulated thyroid tissue during preg-
nancy or adolescence, though even in growing tissues these cancers show a very good prognosis.
The best treatment for nearly all identified malignant thyroid neoplasm is surgery. The aim of the primary treatment is an adequate excision of the primary 
tumour and any loco-regional extension. Considerable controversy still exists over the optimal extent of primary surgical resection. According to the extent 
of the disease, hemithyroidectomy or radical thyroidectomy is performed. As nodal spread is relatively common, initial surgical exploration should include 
careful examination of the central compartment nodes (paratracheal and tracheoesophageal) as well as dissection of clinically suspicious nodes for frozen 
section examination. Nodes in the jugular chains should also be carefully examined with US before surgery and, when suspicious, FNAB should be ob-
tained. If nodal involvement is confirmed, total thyroidectomy and modified radical neck dissection are indicated.
Adjuvant therapies
Thyroid hormones – Endocrine therapy: post-operative oral administration of supraphysiologic oral doses of levothyroxine are used assuming that the sup-
pression of endogenous production of TSH deprives TSH-dependent DTC cells of an important growth-promoting influence and the goal for basal serum 
TSH should be in the 0.1 to 0.4 mIU/L range.
When radical thyroidectomy is performed, the second most frequently used post-operative adjuvant therapy for non-pregnant patients with DTC is radio-
active iodine (RAI, I-131) administered to eradicate persistent neck disease or distant metastatic lesions. This adjunctive therapy is supposed to destroy 
occult microscopic carcinoma within the thyroid remnant by being actively trapped both by normal and pathological thyroid cells, and to facilitate follow-up 
because serum thyroglobulin (HTG) measurements are more reliable after the destruction of residual normal thyroid tissue.
Follow-up
Follow-up is planned according to the stage of the disease and to the extent of the surgery performed. All patients should undergo neck ultrasound and 
serum assay for HTG, HTG antibodies, fT4 and TSH. For thyroidectomized high-risk, non-pregnant patients, I-131 scan is also indicated, and serum HTG 
measurements – performed both with thyroxine deprivation or under rTSH (recombinant human TSH) stimulation – is a useful and reliable marker of 
disease progression or persistence.
In our experience, the best follow-up method to detect loco-regional recurrences is, without question, neck sonography, followed by a meticulous physical 
examination by experienced personnel and, when indicated, ultrasound-guided FNA to confirm clinical suspicion of neck recurrence 41-45.B. gibelli et al.
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mination of pregnancy 4. when surgery is planned during 
pregnancy, it is important to consider both gestational age 
and the type of general anaesthesia. whenever possible, 
the operation should be performed during the second tri-
mester or after delivery 37. During the first trimester, which 
is the organogenesis period, general anaesthetic agents 
may have some teratogenic potential or may increase the 
risk of miscarriage. in the third trimester, surgery may in-
duce premature labour. physiological changes of pregnan-
cy, such as increased heart rate and blood volume, may 
complicate general anaesthesia, and hypotension caused 
by vena cava compression of the uterus during a long 
period in the supine position may cause foetal hypoper-
fusion 1. postponing surgery to at least 6-7 months after 
diagnosis of DTC in the first trimester does not adversely 
affect prognosis; on the other hand, thyroidectomy can 
be safely performed in the second trimester of pregnancy 
or after delivery 15. Thyroxin therapy should be started 
immediately  after  surgery  because  untreated  hypothy-
roidism may expose the mother to a higher risk of disease 
recurrence and may have an adverse effect on cognitive 
function and regular growth of the offspring. regular as-
sessments of TSh and fT4 levels every 6/8 weeks during 
pregnancy and breast-feeding are required to ensure an 
adequate dose of levothyroxine. Follow-up may be carried 
out on a regular basis with ultrasound techniques and thy-
roglobulin assay, as in non-pregnant women. radioiodine 
therapy, when needed, can be safely postponed until after 
breast- feeding.
2. “Cured” patients
Pregnant  patients  with  a  history  of  previously  treated 
DTC with no evidence of recurrent or persistent disease 
by imaging and by thyroglobulin measurement.
whether women treated for thyroid cancer should become 
pregnant was once a matter of concern, but current evi-
dence suggests that DTC should not discourage intended 
pregnancy, with the usual recommendation to postpone it 
Box 2. 
Medullary Thyroid Cancer (MTC) – cancer arising from parafollicular thyroid cells
Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and 
survival rates because of the large geographic variations, mainly due to its familial pattern. Although uncommon, MTC is interesting because of its bio-
chemical and genetic features and clinical association, both in autosomal-dominant inherited syndromes with incomplete penetrance (MEN IIA and IIB), 
and in the non-MEN forms.
Familial cases account for about 30% of MTCs. The occurrence of MTC in both sporadic and familial forms makes the clinical approach to this tumour 
different from that to other thyroid tumours. First, patients with MTC should always be suspected of carrying the genetic form of the disease. Secondly, the 
possible presence of associated conditions, such as pheochromocytoma, should be recognized before submitting patients to thyroidectomy. Lastly, since 
the clinical behaviour of MTC is extremely variable, this tumour represents a true therapeutic challenge.
MTC arises from C cells secreting calcitonin, a 32-amino acid peptide. Calcitonin is the most clinically useful biochemical marker for these tumours, and 
C cell hyperplasia represents a pre-cancerous stage. These neuroendocrine cells are believed to be of neural crest origin, thus having a separate lineage 
from the endoderm-derived follicular thyroid cells. For this reason, in addition to calcitonin-gene products, such as calcitonin CGRP (calcitonin-gene-
related-peptide) and C-CAP (katacalcin), MTC cells express several other biochemical markers that reflect the features of diffuse neuroendocrine system, 
implicated in the pathogenesis of the symptoms (flushing, diarrhoea, carcinoid syndrome or Cushing’s syndrome) that may occur in patients with advanced 
disease. These cells can also produce prostaglandins and other neuroendocrine markers such as chromogranin A, sometimes used together with calcitonin 
and CEA in MTC patients during follow-up.
When dealing with MTC, we should always bear in mind that these patients may be the index-case for one of the familial forms of the disease: pre-
symptomatic screening of relatives of MTC patients enables early diagnosis of this malignancy. Early diagnosis rather than more extensive surgery may 
improve survival and reduce recurrences, mostly in the MEN IIB form of MTC, which is highly aggressive.
Biochemical screening of familial disease consists of serum calcitonin evaluation, and genetic screening of individuals with a RET mutation may also be 
performed. In inherited forms, the initial germline mutation produces multiple foci of cells – the so-called C-cell hyperplasia – that are susceptible to 
tumour formation, and each MTC is the result of a second cell transformation in one of these susceptible clones.
Primary MTC lesions become visible at echography as solid masses, often with calcifications. Fine needle aspiration shows a mixture of round, polyhedral 
and spindle-shaped cells that may seem undifferentiated, and look like a variable amount of extra-cellular amyloid.
MTCs, like other neuroendocrine tumours, can express somatostatin receptors. Follow-up of MTC patients suspected for recurrence can therefore be 
performed by using the somatostatin analogue octreotide (octreoscan). The presence of somatostatin receptors provides the basis for treatment with long-
acting analogues of somatostatin or with Y-octreotide (DOTATOC) in some patients.
MTC is somewhat more aggressive than papillary or follicular carcinoma. It locally extends into lymph nodes and into the surrounding muscles and trachea, 
and may invade lymphatic and blood vessels and metastasize in lungs, bones and liver. Sporadic MTC tumours are often monolateral with a single localiza-
tion, while familial forms are mostly bilateral and often multifocal or diffuse. For these reasons, total thyroidectomy appears to be the appropriate approach 
to MTC. Central neck and upper mediastinum clearance and, in addition, mono or bilateral node dissection (depending on the extent of nodal involvement) 
is also advisable. The most appropriate treatment for clinical N0 tumours is still a matter of debate, but most surgeons prefer prophylactic node dissection 
because MTC metastasize in regional lymph nodes at a very early stage.
Surgery is the only treatment which is considered potentially curative for metastatic or recurrent medullary carcinoma. The role of radiotherapy is contro-
versial as MTC is generally not believed to be radio-sensitive. Therapy with long-acting somatostatin analogues has been tested in metastatic disease, with 
some positive benefots in most patients. Radioactive iodine is ineffective because I-131 uptake by MTC cells is negligible. No reliably effective chemothera-
peutic regimen has been identified. New drugs with anti-angiogenetic, anti-tyrosine kinase and anti-VEGF effects are currently under observation.
In conclusion, there are several ways to expedite the diagnosis of MTC and to follow-up patients after surgery: biochemical markers (e.g. CEA, calcitonin, 
katacalcin, chromogranin-A according to tumour staining), and scanning with specific ligands such as octreotide. Furthermore, there are new therapeutic 
approaches under validation for advanced or recurrent disease 46-48.Thyroid cancer in pregnant women
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to at least 6 months after radioiodine therapy. in spite of 
the theoretical proliferative stimulation caused by hCg 
and placental growth factors, published data indicate that 
there is no evidence that thyroid cancer can be influenced 
by pregnancy. in addition, follow-up studies have shown 
no significant increase in risk. usually, patients are rec-
ommended to postpone pregnancy to 6-12 months after 
radioiodine (i-131) treatment to avoid a potentially higher 
risk of miscarriage in the first few months after radioiod-
ine therapy and to allow time enough to exclude residual 
disease requiring further treatment 4 14 38. miscarriages or 
premature birth have raised concern about the use of radio-
active iodine in a childbearing age due to the known muta-
genic effect of radiation and the theoretical possibility that 
it may affect germ cells, thereby causing genetic damage, 
congenital  abnormalities  and  malignancy  in  offspring. 
virtually any person treated with any dosage of i-131 is 
at potential risk, but experimental evidence in animals 
and follow-up studies in humans has failed to reveal any 
statistically significant effects of i-131 on chromosomal 
abnormalities, congenital malformation or childhood can-
cers. in a large retrospective study, Dottorini et al. evalu-
ated fertility and the long-term effects of i-131 therapy 
in 815 women. Among those children born from i-131 
treated women, the authors found only one case of ven-
tricular septal defect and patent ductus arteriosus 22 39 40. A 
possible increase in the rate of miscarriages has been re-
ported to occur in the early period after therapy, but it re-
mains uncertain whether abortion can be caused either by 
i-131 itself, by the thyroid autoimmunity often associated 
with disease or by the hypothyroid-hyperprolactinaemic 
status accompanying i-131 therapy. At present, consensus 
has been reached on the fact that radioiodine treatment of 
DTC does not affect pregnancy outcome and does not ap-
pear to be associated with any genetic risk, with the usual 
recommendation to delay pregnancy for 6-12 months af-
ter radioiodine exposure, even if there is no evidence that 
pregnancy before this period could lead to a less favour-
able outcome 22 38.
3. Persistent or recurrent disease
Pregnant patients with the evidence of persistent disease 
despite therapy.
management of these patients and providing evidence-
based  advice  are  obviously  extremely  difficult  tasks. 
patients with active DTC can be reassured that, as men-
tioned above, pregnancy itself does not appear to increase 
disease progression, and therefore a gap in treatment dur-
ing pregnancy is not contraindicated. when a simple in-
crease in serum htg levels is observed, further therapy is 
not necessary. For patients with local recurrent disease, 
ultrasound controls by skilled hands is of outmost impor-
tance, both to help surgeons in selecting tissues for exci-
sion and to perform local therapy, such as alcoholization 
of small lesions. For patients with advanced disease, ul-
trasound control of tissue growth can help in therapeutic 
decisions, such as timing of surgery. whenever possible, 
surgery should be carried out during the second trimester 
or after delivery, as for newly diagnosed thyroid cancer.
For any patient, both with first diagnosis or recurrent dis-
ease, post-operative therapy for DTC is based on the ad-
ministration of supraphysiologic “suppressive” oral doses 
of levothyroxine. This treatment has been widely used for 
more than 40 years, with the assumption that suppression 
of endogenous TSh deprives TSh-dependent DTC cells 
of the most important growth factor. Therefore, thyroxine 
therapy aims at suppressing pituitary secretion of TSh, 
as indicated by serum TSh levels below 0.05 miu/l. in 
univariate analyses, thyroxine therapy apparently helps 
decrease cancer-related death rates among patients with 
pTC. many series have reported reduced rates of tumour 
recurrence both in pTC and in FTC. Doses of l-thyroxine 
greater than 150/200 μg (at least 2 μg/kg/day) are usually 
needed to maintain maternal serum-free thyroxin concen-
trations within the upper third of the reference range and 
to suppress TSh levels. usually the dosage needs to be in-
creased as early as during the fifth week of gestation, and 
fT4 TSh monitoring is recommended every 6 weeks for 
adequate adjustment of dosage. After delivery, thyroxine 
dose can be gradually reduced to pre-pregnancy levels, 
while TSh levels should be constantly monitored 10 15.
patients with mTC whose tumours deriving from C cells 
are not TSh-dependent do not require suppressive thera-
py, but only thyroxine replacement therapy after surgery, 
and the dosages are the same as those used for hypothy-
roidism.
pregnancy status requires much more accuracy in assessing 
levothyroxine dosage to protect the foetus from maternal 
hypothyroidism because, as mentioned above, the mother 
is the only source of thyroid hormones for the embryo in 
the first trimester of pregnancy. with regards to pharma-
cokinetics, oral dosing produces therapeutic effects within 
3-5 days. Approximately 40-80% of the oral dose is ab-
sorbed, with peak serum levels measured within 2-4 hour, 
and the half-life of the administered dose is approximately 
1 week. The extent of absorption is increased in fasting sta-
tus and decreased if there is inadequate intestinal absorp-
tion, often caused by other drugs, such as ferrous sulphate. 
Therefore, during pregnancy, thyroxin and ferrous sulphate 
doses should be spaced by at least 4 hours. There is limited 
but still important placental transfer of maternal T4 to the 
foetus 18, while placental type iii deiodinase catalyzes the 
conversion of T4 to the more active form reverse-T3, which 
crosses the placental barrier, and to the less active 3,3’-dii-
odothyronine (T2), representing a homeostatic mechanism 
for maintaining T3 production in the placenta when mater-
nal serum T4 concentrations are modified 18.
Frequent monitoring and adjustment of l-T4 dosages are 
very important because of large fluctuations of T4 me-B. gibelli et al.
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tabolism during pregnancy; calcium and D vitamin sup-
plementation, often indispensable, must be carefully tai-
lored 23 24.
Conclusions
when  treating  thyroid  cancer  in  pregnancy,  3  factors 
should be considered:
1. The effect of cancer on pregnancy: no metastasis to 
placenta or foetus – no iugr.
  pregnancy does not seem to be compromised by thy-
roid cancer.
2. The effect of pregnancy on cancer: In vitro accelerated 
cell growth, no effect seen in vivo.
  Survival and disease-free intervals identical in pregnant 
and non-pregnant women
3. The effects of management modalities on pregnancy 
outcome: no i-131, tailored therapy.
  Critical monthly adjustment of levothyroxine therapy: 
maintain fT4 in the upper third of reference range.
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